| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | POLg1 |
| Uniprot No | P54098 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-1239aa |
| 氨基酸序列 | MHHHHHHDYKDDDDKSRLLWRKVAGATVGPGPVPAPGRWVSSSVPASDPS DGQRR RQQQQQQQQQQQQQPQQPQVLSSEGGQLRHNPLDIQMLSRGLH EQIFGQGGEMP GEAAVRRSVEHLQKHGLWGQPAVPLPDVELRLPPLYG DNLDQHFRLLAQKQSLPYL EAANLLLQAQLPPKPPAWAWAEGWTRYGP EGEAVPVAIPEERALVFDVEVCLAEGT CPTLAVAISPSAWYSWCSQRL VEERYSWTSQLSPADLIPLEVPTGASSPTQRDWQEQ LVVGHNVSFDRA HIREQYLIQGSRMRFLDTMSMHMAISGLSSFQRSLWIAAKQGKHK VQP PTKQGQKSQRKARRGPAISSWDWLDISSVNSLAEVHRLYVGGPPLEKEPR ELFV KGTMKDIRENFQDLMQYCAQDVWATHEVFQQQLPLFLERCPHPV TLAGMLEMGVSY LPVNQNWERYLAEAQGTYEELQREMKKSLMDLANDA CQLLSGERYKEDPWLWDLE WDLQEFKQKKAKKVKKEPATASKLPIEGA GAPGDPMDQEDLGPCSEEEEFQQDVM ARACLQKLKGTTELLPKRPQHL PGHPGWYRKLCPRLDDPAWTPGPSLLSLQMRVTP KLMALTWDGFPLHY SERHGWGYLVPGRRDNLAKLPTGTTLESAGVVCPYRAIESLYR KHCLE QGKQQLMPQEAGLAEEFLLTDNSAIWQTVEELDYLEVEAEAKMENLRAAV P GQPLALTARGGPKDTQPSYHHGNGPYNDVDIPGCWFFKLPHKDGNSC NVGSPFAKD FLPKMEDGTLQAGPGGASGPRALEINKMISFWRNAHKRI SSQMVVWLPRSALPRAVI RHPDYDEEGLYGAILPQVVTAGTITRRAVE PTWLTASNARPDRVGSELKAMVQAPPG YTLVGADVDSQELWIAAVLGD AHFAGMHGCTAFGWMTLQGRKSRGTDLHSKTATTV GISREHAKIFNYG RIYGAGQPFAERLLMQFNHRLTQQEAAEKAQQMYAATKGLRWY RLSDE GEWLVRELNLPVDRTEGGWISLQDLRKVQRETARKSQWKKWEVVAERAWK GGTESEMFNKLESIATSDIPRTPVLGCCISRALEPSAVQEEFMTSRVN WVVQSSAVDY LHLMLVAMKWLFEEFAIDGRFCISIHDEVRYLVREEDR YRAALALQITNLLTRCMFAYK LGLNDLPQSVAFFSAVDIDRCLRKEVT MDCKTPSNPTGMERRYGIPQGEALDIYQIIEL TKGSLEKRSQPGP |
| 预测分子量 | 141 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于POLg1重组蛋白的虚构参考文献示例，供参考：
1. **文献名称**：Recombinant Human POLG1: Expression, Purification, and Enzymatic Characterization
**作者**：Smith J. et al.
**摘要**：本研究报道了人源POLg1重组蛋白在大肠杆菌中的高效表达与纯化，并证实其具有依赖DNA的聚合酶活性及3'→5'外切酶校正功能，为线粒体DNA修复机制研究提供工具。
2. **文献名称**：Structural Insights into POLG1 Mutations Linked to Mitochondrial Disorders
**作者**：Chen L. & Wang H.
**摘要**：通过X射线晶体学解析POLg1重组蛋白的突变体结构，揭示致病突变(如A467T)如何破坏蛋白构象，导致线粒体DNA复制缺陷及神经退行性疾病。
3. **文献名称**：Functional Complementation of Yeast MIP1 with Human POLG1 in Mitochondrial Genome Maintenance
**作者**：Gomez R. et al.
**摘要**：利用酿酒酵母模型，证明重组人POLg1可恢复MIP1缺陷株的线粒体功能，验证其保守的DNA合成能力及与疾病相关突变的致病机理。
4. **文献名称**：High-Throughput Screening for POLG1 Inhibitors Using Recombinant Protein Assays
**作者**：Kim S. et al.
**摘要**：基于POLg1重组蛋白建立高通量药物筛选平台，鉴定出小分子抑制剂C12可特异性阻断其聚合酶活性，为抗癌药物开发提供新靶点。
注：以上文献为示例性质，实际引用需查询PubMed、Web of Science等数据库获取真实研究。
POLg1. also known as DNA polymerase gamma subunit 1. is the catalytic subunit of DNA polymerase gamma (Pol γ), the primary enzyme responsible for mitochondrial DNA (mtDNA) replication and repair in eukaryotic cells. Encoded by the nuclear POLG gene, POLg1 contains conserved polymerase and exonuclease domains critical for its enzymatic activity. Its function is tightly linked to mitochondrial genome integrity, as errors in mtDNA replication or repair can lead to mitochondrial dysfunction, a hallmark of aging and various diseases.
Recombinant POLg1 protein is engineered using expression systems like *E. coli* or insect cells to study its biochemical properties, structure-function relationships, and interactions with accessory subunits (e.g., POLg2) or mitochondrial proteins. This tool has been pivotal in characterizing POLG mutations associated with mitochondrial disorders, such as progressive external ophthalmoplegia (PEO), ataxia-neuropathy syndromes, and early-onset Parkinsonism. Over 300 pathogenic POLG variants have been identified, many impairing POLg1’s polymerization fidelity or proofreading capacity, leading to mtDNA deletions/point mutations.
Research on recombinant POLg1 also explores its role in antiviral drug toxicity (e.g., nucleoside analogs like AZT that inhibit mtDNA replication) and aging-related mtDNA instability. Structural studies using recombinant protein have revealed mechanisms of DNA binding, nucleotide selection, and mutation-induced dysfunction. Additionally, it serves as a target for drug screening to mitigate mitochondrial toxicity or enhance replication fidelity. The development of recombinant POLg1 continues to bridge gaps in understanding mitochondrial biology and therapy development for mitochondrial diseases.
×
